Data were presented at Digestive Disease Week 2012 in San Diego...Data were presented at Digestive Disease Week 2012 in San Diego

Neurocrine Biosciences Inc., of San Diego, reported Phase II results showing that infusion of urocortin 2 in patients with acute decompensated heart failure was generally well tolerated and there were no treatment-related serious adverse events

Ceregene Inc., of San Diego, said data presented at the annual meeting of the American Society for Gene and Cell Therapy in Philadelphia demonstrated biologically active expression of neurturin and enhanced dopamine activity in Parkinson's disease four years following treatment with CERE-120 (AAV2-neurturin

Elevation Pharmaceuticals Inc., of San Diego, reported results from a Phase IIb study of EP-101 in patients with chronic obstructive pulmonary disease, showing that those with moderate disease treated with the inhalation solution formulation of long-acting muscarinic antagonist glycopyrrolate had a clinically meaningful and statistically significant improvement in lung function vs

Separately, Cytokinetics reported preclinical data in a poster presentation at the 2012 Experimental Biology Annual Conference in San Diego

OncoSec Medical Inc., of San Diego, said an interim analysis of data from 81 subjects in a European Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck showed that OMS ElectroChemotherapy (bleomycin) provided local tumor control and quality-of-life outcomes that compared favorably with standard surgical outcomes

The single-dose data were presented at the Cambridge Healthtech Institute's 5th Annual HCV Drug Discovery meeting in San Diego

Marshall Edwards Inc., of San Diego, said it received FDA clearance for a Phase I trial testing intravenous ME-344, a mitochondrial inhibitor, in patients with solid refractory tumors

Stemedica Cell Technologies Inc., of San Diego, said a human trial showed that transplanted ischemic tolerant mesenchymal stem (itMSCs) cells yielded a significant improvement in pumping function of the left ventrical in heart attack patients

Protox Therapeutics Inc., of San Diego, completed dosing of the fourth and final patient cohort in its transrectal study of PRX302 in benign prostatic hyperplasia

Neurocrine Biosciences Inc., of San Diego, said a post-hoc analysis of a Phase II trial testing NBI-98854 in 37 tardive dyskinesia patients demonstrated a clinically meaningful and statistically significant improvement in symptoms for subjects receiving the 50-mg once-daily dose at the end of two weeks of active treatment vs

Optimer Pharmaceuticals Inc., of San Diego, Calif., published results from a Phase III trial of Dificid (fidaxomicin) for Clostridium difficile infection (CDI) that showed similar cure rates as oral vancomycin

MediciNova Inc., of San Diego, said it completed enrollment in its Phase II trial of MN-221, a selective beta(2)-adrenergic receptor agonist, in acute exacerbations of asthma

Cytori Therapeutics Inc., of San Diego, said the European Journal of Surgical Oncology published data from the 71-patient RESTORE-2 study testing autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for reconstruction of the breast after cancer surgery...The Phase II substudy results were presented at the American Academy of Dermatology meeting in San Diego

Marshall Edwards Inc., of San Diego, submitted an investigational new drug application (IND) to the FDA for oncology drug candidate ME-344, its lead mitochondrial inhibitor...ViroPharma Inc., of Exton, Pa., and Halozyme Therapeutics Inc., of San Diego, presented data from a Phase II trial of Cinryze (C1 esterase inhibitor) in combination with Halozyme's Enhanze technology in patients with hereditary angioedema

Vical Inc., of San Diego, said the Naval Medical Research Center (NMRC) began a Phase I trial of tetravalent dengue DNA vaccine formulated with its Vaxfectin adjuvant

BrainCells Inc., of San Diego, completed the Phase I single-ascending-dose study of BCI-838 and initiated the Phase I multiple-ascending-dose study of the oral prodrug for BCI-632, a compound aimed at central nervous system disorders...Essentialis Inc., of San Diego, said the double-blind, placebo-controlled Phase IIb trial of investigational compound DCCR demonstrated a 30 percent to 40 percent reduction in triglyceride (TG) levels in patients whose TG levels exceeded 500 mg/dL...Polaris Group, of

OncoSec Medical Inc., of San Diego, said the first patient has been dosed in a Phase II trial testing its OMS ElectroImmunotherapy in advanced-stage cutaneous and in-transit metastatic melanoma

OncoSec Medical Inc., of San Diego, said the first patient has been dosed in a Phase II trial testing its OMS ElectroImmunotherapy in advanced-stage cutaneous and in-transit metastatic melanoma